Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 6 hours ago
Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought
about 6 hours ago
Sanofi and Wave Life Sciences are using their time at the annual...
Vincetage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
about 10 hours ago
Vincentage Pharma’s oral GLP-1 agonist has been tied to mean weight loss...
BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
about 11 hours ago
BioMarin’s $270 million bet on Inozyme’s enzyme replacement therapy looks in trouble...
After rare disease flop, cash-strapped Quince finds salvation in reverse merger
about 12 hours ago
After launching a hunt for strategic alternatives in January following a phase...
Nominations now open for Fierce Biotech's 2026 Fierce 15
about 12 hours ago
It's time to kick off our annual hunt for the latest crop...
Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
about 13 hours ago
Vincentage Pharma’s oral GLP-1 agonist has been tied to mean weight loss...
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
about 13 hours ago
Regeneron has ponied up $125 million in cash and an equity investment...
Boston Scientific funnels $1.5B into MiRus, with option to buy TAVR system
about 14 hours ago
Acquisitive Boston Scientific is making deals again with a major investment play...
Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3
about 17 hours ago
Ipsen has shared phase 2 data on its long-acting neurotoxin, reporting an...
Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial
about 17 hours ago
A phase 3 trial of Regeneron’s LAG-3 inhibitor has missed its primary...
Ardent Health taps Fujifilm’s AI-enabled patient imaging platform
about 20 hours ago
Fujifilm Healthcare Americas Corp. has signed a deal with Ardent Health to...
Executing biomarker-driven oncology trials
3 days ago
Why biomarker-driven oncology trials require new thinking across patient recruitment, assay development...